139 related articles for article (PubMed ID: 3194187)
1. Alternating chemotherapy and radiation therapy in the treatment of advanced Hodgkin's disease.
Grigoraki V; Merle-Beral H; Touboul E; Gabarre J; Lesty C; Binet JL
Nouv Rev Fr Hematol (1978); 1988; 30(4):219-24. PubMed ID: 3194187
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
Viviani S; Bonfante V; Santoro A; Zanini M; Devizzi L; Di Russo AD; Soncini F; Villani F; Ragni G; Valagussa P; Bonadonna G
Cancer J Sci Am; 1999; 5(5):275-82. PubMed ID: 10526668
[TBL] [Abstract][Full Text] [Related]
3. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
5. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
[TBL] [Abstract][Full Text] [Related]
7. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
9. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
10. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
12. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of advanced Hodgkin's disease: an analysis of 128 cases].
Zhou L; Wang Q; Feng F
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):333-5. PubMed ID: 11778565
[TBL] [Abstract][Full Text] [Related]
14. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
Tsushita K; Utsumi M; Shimoyama M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease.
Young CW; Straus DJ; Myers J; Passe S; Nisce LZ; Lee BJ; Koziner B; Arlin Z; Kempin S; Gee T; Clarkson BD
Cancer Treat Rep; 1982 Apr; 66(4):907-14. PubMed ID: 7042090
[TBL] [Abstract][Full Text] [Related]
17. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
18. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
19. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?
Mundt AJ; Connell PP; Mansur DB
Radiat Oncol Investig; 1999; 7(6):353-9. PubMed ID: 10644058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]